February 12, 2026

FDA Approves Device for Pancreas Care

In the phase 3 PANOVA-3 trial, adding Tumor Treating Fields therapy to gemcitabine and nab-paclitaxel was associated with improved overall survival and delayed pain progression in adults with locally advanced pancreatic cancer.

Conexiant

February 10, 2026

Why Scientists Are Revisiting a Polarizer

The nation’s top cancer institute takes a closer look at a disputed drug.

KFF Health News

February 04, 2026

FDA Expands HPV Primary Screening Options

Regulatory action broadens available approaches for cervical cancer screening in US clinical practice.

Conexiant

January 27, 2026

The Exam Room Is Listening Now

As AI quietly enters exam rooms, physicians report real relief—and real concerns about accuracy, trust, and control.

KFF Health News

December 10, 2025

Is WHO Mpox Monitoring Window Too Short?

New data challenge WHO's 21-day observation window, as nearly one-quarter of infections develop rash after recommended surveillance period ends.

Conexiant

November 26, 2025

FDA Grants Accelerated Approval of Voyxact

The subcutaneous injection offers a new option for adults at risk of progression to kidney failure.

Conexiant

November 18, 2025

Plozasiran Wins FDA Nod for FCS

Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.

Conexiant

November 06, 2025

‘Wasteful’? Doctors Call It Essential

Proposed cuts to the Hospital Preparedness Program may limit hospitals’ capacity to manage pandemics, natural disasters, and mass-casualty events affecting U.S. health systems.

KFF Health News

November 04, 2025

FDA Approves First Drug for Thymidine Kinase 2 Deficiency

First-ever treatment shows significant survival benefit in matched-pair analysis of this ultra-rare mitochondrial depletion syndrome.

Conexiant